Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).

被引：0
|
作者：
Lombana Quinonez, Milton Alberto
Milena Torres, Ana
Gonzalez, Guido
机构：
[1] Ctr Integral Canc Clin Occidente, Cali, Colombia
[2] Nalt Med Solut, Cali, Colombia
[3] Clin Occidente, Cali, Colombia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17070
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer
    Tassinari, Davide
    Tamburini, Emiliano
    Gianni, Lorenzo
    Drudi, Fabrizio
    Fantini, Manuela
    Santelmo, Carlotta
    Stocchi, Lucia
    Montanari, Francesco
    Sartori, Sergio
    REVIEWS ON RECENT CLINICAL TRIALS, 2016, 11 (04) : 317 - 323
  • [32] Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
    Lage, Daniel E.
    Michaelson, M. Dror
    Lee, Richard J.
    Greer, Joseph A.
    Temel, Jennifer S.
    Sweeney, Christopher J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1181 - 1188
  • [33] ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Holzbeierlein, Jeffrey M.
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris Yakovlevich
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Baron, Benoit
    Chen, Lucy F.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer
    Voskoboynik, Mark
    Staffurth, John
    Malik, Zafar
    Sweeney, Christopher
    Chowdhury, Simon
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (11) : 1253 - 1256
  • [35] Erstlinientherapie beim metastasierten hormonsensitiven Prostatakarzinom (mHSPC)First-line treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    H. Rexer
    S. Feyerabend
    M. Graefen
    Forum, 2023, 38 (3) : 238 - 239
  • [36] Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
    Kenrick Ng
    Shievon Smith
    Jonathan Shamash
    Oncology and Therapy, 2020, 8 : 209 - 230
  • [37] Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
    Ng, Kenrick
    Smith, Shievon
    Shamash, Jonathan
    ONCOLOGY AND THERAPY, 2020, 8 (02) : 209 - 230
  • [38] EFFICACY AND FEASIBILITY OF ADDITIONAL CYCLES OF DOCETAXEL IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF UROLOGY, 2023, 209 : E388 - E389
  • [39] Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer
    Mager, Rene
    Savko, Olga
    Boehm, Katharina
    Thomas, Anita
    Dotzauer, Robert
    Borgmann, Hendrik
    Jaeger, Wolfgang
    Thomas, Christian
    Haferkamp, Axel
    Hoefner, Thomas
    Tsaur, Igor
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (12) : 999 - 1005
  • [40] Management of Metastatic Hormone-Sensitive Prostate Cancer
    Bernard, Brandon
    Sweeney, Christopher J.
    CURRENT UROLOGY REPORTS, 2015, 16 (03)
12345